| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 32.73 Billion | USD 66.53 Billion | 8.2% | 2024 |
FrequentlyAsked Questions
As per the report from the World Health Organization, it is found that one in three people is overweight. Such statistics are due to the increasing consumption of tobacco and liquor, which is likely to scale up the risk of obesity. Such a landscape further creates critical hypertension, which causes thrombosis-associated problems. Therefore, it is likely to fuel the growth of the global thrombosis drug market exponentially in the forthcoming years.
According to a study, the global thrombosis drug market size was worth around USD 32.73 Billion in 2024 and is expected to reach USD 66.53 Billion by 2034.
The global thrombosis drug market is expected to grow at a CAGR of 8.2% during the forecast period.
North America is expected to dominate the thrombosis drug market over the forecast period.
Leading players in the global thrombosis drug market include Pfizer, Aspen Pharmacare Holdings Limited, Bayer AG, AstraZeneca plc, Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, Baxter International Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline plc, among others.
The report explores crucial aspects of the thrombosis drug market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients